[Controlled clinical trial of a new substance with hepatotropic activity, carried out with an experimental cross-over plan in double-blind conditions].
D000328:Adult; D000368:Aged; D000437:Alcoholism / Q000150:complications; D000596:Amino Acids / Q000627:therapeutic use; D001224:Aspartic Acid / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008107:Liver Diseases / Q000188:drug therapy*; D008111:Liver Function Tests; D008722:Methods; D008875:Middle Aged; D010919:Placebos; D013386:Succinates / Q000627:therapeutic use*; D014149:Tranquilizing Agents / Q000009:adverse effects
D000596:Amino Acids; D007093:Imidazoles; D010919:Placebos; D013386:Succinates; D014149:Tranquilizing Agents; D001224:Aspartic Acid
Sperimentazione clinica controllata di una nuova sostanza ad azione epatotrofa, secondo un disegno sperimentale incrociato (cross-over) in condizioni di doppia cecità.